Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Growth Analysis: How Will Revenue Trend Over The Forecast Period?
The generative artificial intelligence (AI) in pharmaceutical market has experienced substantial growth in recent years. Its value is expected to rise from $2.43 billion in 2025 to $3.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 31.2%. The expansion observed historically can be ascribed to several factors, including increasing r&d investments in pharmaceuticals, a rise in chronic diseases, the growing adoption of AI in early-stage drug discovery, the expansion of the biologics market, and the availability of large-scale molecular datasets.
The generative artificial intelligence (AI) in pharmaceutical market size is projected to experience substantial expansion in the coming years. It is anticipated to reach $9.36 billion in 2030, demonstrating a compound annual growth rate (CAGR) of 30.9%. This expansion throughout the forecast period stems from advancements in generative AI algorithms, the development of precision medicine, an increase in virtual clinical trials, the growing need for biologics optimization, and the integration of AI with cloud computing. Significant trends during this period are expected to involve AI-driven drug design optimization, predictive molecular modeling, virtual screening of compound libraries, the creation of personalized medicine, and biopharmaceutical efficacy simulation.
Get A Free Sample Report With In-Depth Market Insights:
Generative Artificial Intelligence (AI) In Pharmaceutical Market Growth Factors Behind Sustained Expansion
The growing emphasis on individualized healthcare is anticipated to accelerate the expansion of generative artificial intelligence (AI) within the pharmaceutical market moving ahead. This approach involves customizing medical treatments for each patient, considering their unique characteristics, requirements, and preferences, which stem from genetic, environmental, and lifestyle elements. The heightened attention on personalized medicine results from breakthroughs in genetic research and technology, enabling the creation of more accurate and potent therapies designed for specific patients. Within the pharmaceutical sector, personalized medicine utilizes generative AI to formulate bespoke drug therapies, thereby enhancing treatment effectiveness and patient results. A relevant example is the report from February 2024 by the Personalized Medicine Coalition, a US-based non-profit, stating that the FDA sanctioned 16 new personalized treatments for individuals with rare diseases in 2023, a significant rise from six in 2022. Consequently, the heightened emphasis on personalized medicine is serving as a catalyst for the growth of generative artificial intelligence (AI) in the pharmaceutical market.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Segment Outlook: Which Categories Are Growing Fastest?
The generative artificial intelligence (AI) in pharmaceutical market covered in this report is segmented –
1) By Type: Small Molecule, Large Molecule
2) By Technology: Deep Learning, Natural Language Processing, Querying Method, Context-Aware Processing, Other Technologies
3) By Application: Clinical Trial Research, Drug Discovery, Research And Development, Other Applications
Subsegments:
1) By Small Molecule: Drug Discovery And Design, Lead Optimization For Small Molecule Compounds, Predictive Modeling For Pharmacokinetics And Toxicity, Virtual Screening Of Compound Libraries, Personalized Medicine Approaches For Small Molecule Therapies
2) By Large Molecule: Biologics Discovery And Development, Monoclonal Antibody Design, Protein Engineering And Optimization, Vaccine Development And Optimization, Predictive Models For Biopharmaceutical Efficacy And Safety.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Industry Trends Fueling Future Revenue Growth
Leading firms in the generative artificial intelligence (AI) pharmaceutical sector are innovating with products like AI healthcare microservices to optimize drug discovery workflows. These microservices are modular, cloud-native solutions leveraging AI to enhance healthcare operations including drug discovery, medical imaging, and diagnostics. For example, in March 2024, Nvidia Corporation, a technology company headquartered in the US, introduced its generative AI microservices. These offerings incorporate optimized NIM AI models and workflows, complete with APIs for developing cloud-native applications. They provide capabilities such as advanced imaging, natural language processing, speech recognition, and digital biology. Essential tools like Parabricks, MONAI, NeMo, Riva, and Metropolis are available as CUDA-X microservices, thereby improving processes in drug discovery and genomics.
Generative Artificial Intelligence (AI) In Pharmaceutical Market Leading Companies And Competitive Benchmarking
Major companies operating in the generative artificial intelligence (AI) in pharmaceutical market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Fujitsu Limited, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., NVIDIA Corporation, Conduent Incorporated, XtalPi Inc., Insilico Medicine Inc., Numerate Inc., Atomwise Inc., BenevolentAI Limited
View The Full Generative Artificial Intelligence (AI) In Pharmaceutical Market Report:
Generative Artificial Intelligence (AI) In Pharmaceutical Market Top Region By Revenue And Market Share
North America was the largest region in the generative artificial intelligence (AI) in the pharmaceutical market in 2025. The regions covered in the generative artificial intelligence (AI) in pharmaceutical market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Wasay has over a decade of experience in market research, data modelling, and analytics, with prior experience at GlobalData and Decision Tree Consulting Services. At The Business Research Company , he leads research operations across syndicated studies, customized consulting engagements, and the Global Market Model platform. His professional experience includes supporting organizations such as Boston Consulting Group, KPMG, and Ernst & Young. Wasay holds a degree in Electronics and Communications Engineering, postgraduate management qualifications from International Management Institute Belgium and Indian School of Business and Entrepreneurship, and completed the Integrated Program in Business Analytics from Indian Institute of Management Indore.
